Shay Capital’s VistaGen Therapeutics VTGN Stock Holding History

Shay Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,200	Closed	-$13.4K	–	654
2025 Q4	$13.4K	Buy	+20,200	New	+$73K	﹤0.01%	476

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Shay Capital's VTGN Position: Q2 2026 in Review

Shay Capital sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 144,452 shares — an estimated $82.6K sold.

Shay Capital first reported a position in VTGN in Q1 2026 and held it in 1 quarter. The position peaked at $82.6K in Q1 2026. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

Shay Capital reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
Shay Capital sold 144,452 VistaGen Therapeutics shares in Q2 2026, an estimated $82.6K.
Shay Capital first reported a position in VistaGen Therapeutics in Q1 2026 and held it in 1 quarter.
Shay Capital's VistaGen Therapeutics position peaked at $82.6K in Q1 2026.
49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.